Concepedia

A Bispecific Enediyne-Energized Fusion Protein Containing Ligand-Based and Antibody-Based Oligopeptides against Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Shows Potent Antitumor Activity

Xiaofang Guo, Xiaofei Zhu, Yue Shang, Shenghua Zhang, Yong‐Su Zhen

Clinical Cancer Research · 2010 · 44 citations · 25 references

DOI

Abstract

A ligand-based and an antibody-based oligopeptide fused to the enediyne antibiotic LDM created a new bispecific fusion protein with low molecular weight and more potent in vitro and in vivo antitumor activity (than momospecific fusion proteins).

References

25

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

Diana Graus-Porta · The EMBO Journal · 1997 · 1.6K citations · Full text

, , +11

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Gottfried E. Konecny, Mark D. Pegram, Natarajan Venkatesan et al. · Cancer Research · 2006 · 904 citations

, , +11

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 737 citations

, , +16

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Stacy L. Moulder, F. Michael Yakes, Senthil K. Muthuswamy et al. · PubMed · 2001 · 548 citations

, , +15

Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site

Robert Schier, Adrian M. McCall, Gregory P. Adams et al. · Journal of Molecular Biology · 1996 · 381 citations

, , +7